AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3888594 — intervention group
Group type: COMPARATOR
Intervention: Intragastric magnesium-aluminium-hydroxide concentrate (antacid, group B)
Number of subjects: 125
Study 31855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of serum at delivery from pregnant women
Number of subjects: 1823
Study 31855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of maternal, cord and infant blood samples
Number of subjects: 1823
Study 31855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for group B streptococcus
Number of subjects: 1823
Study 31855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of blood samples from infants born to colonised women
Number of subjects: 1823
Study 31855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of maternal and infant blood and bacterial isolates
Number of subjects: 1823
Study 27701372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)-assisted procedure (Group B)
Number of subjects: 58
Study 27701372 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique (Group A)
Number of subjects: 58
Study 27111879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining (switching from rearfoot strike to forefoot strike)
Number of subjects: 16
Study 27111879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 24997616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 80
Study 24997616 — intervention group
Group type: COMPARATOR
Intervention: Steroid + bupivacaine
Number of subjects: 80
Study 22992072 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (twice-daily, 240 mg)
Number of subjects: 0
Study 22992072 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (thrice-daily, 240 mg)
Number of subjects: 0
Study 22992072 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study 22992072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22992072 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (twice-daily)
Number of subjects: 0
Study 22992072 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (thrice-daily)
Number of subjects: 0
Study 20808333 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-abundant diet (449 mg phytosterols/2000 kcal)
Number of subjects: 20
Study 20808333 — intervention group
Group type: COMPARATOR
Intervention: Phytosterol-poor diet (126 mg phytosterols/2000 kcal)
Number of subjects: 20
Study 18055931 — intervention group
Group type: EXPERIMENTAL
Intervention: GP education programme and access to LEO CAT
Number of subjects: 150
Study 18055931 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 150
Study 16236854 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 40
Study 16236854 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic smokers
Number of subjects: 40
Study 16236854 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients who smoked the same morning
Number of subjects: 40
Study 16236854 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 40
Study 14601482 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 34
Study 14601482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 9925124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (15 g/d)
Number of subjects: 20
Study 9925124 — intervention group
Group type: COMPARATOR
Intervention: Glucose as a placebo (4 g/d)
Number of subjects: 20
Study 7768081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lipo-PGE1/glucagon-insulin therapy (group B)
Number of subjects: 29
Study 7768081 — intervention group
Group type: COMPARATOR
Intervention: Glucagon-insulin therapy only (group A)
Number of subjects: 29
Study 1690483 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin HCl
Number of subjects: 39
Study 1690483 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 6998537 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic co-trimoxazole (single dose)
Number of subjects: 68
Study 6998537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 68
Study 31112457 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 session psychiatric standard treatment with added Plan Analysis and Motive Oriented Therapeutic Relationship
Number of subjects: 36
Study 31112457 — intervention group
Group type: COMPARATOR
Intervention: 10 session psychiatric standard treatment without the added Plan Analysis and Motive Oriented Therapeutic Relationship
Number of subjects: 36
Study 28330794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404
Study 28330794 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study 25028983 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion (WI, 30 °C)
Number of subjects: 8
Study 25028983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool water immersion (CI, 26.7 °C)
Number of subjects: 8
Study 25028983 — intervention group
Group type: COMPARATOR
Intervention: No immersion (NI)
Number of subjects: 8
Study 22948339 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy
Number of subjects: 205
Study 22948339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 21782168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization with the ESS 305 device by experienced physicians
Number of subjects: 578
Study 21782168 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic sterilization with the ESS 305 device by novice physicians
Number of subjects: 578
Study 21782168 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 578
Study 19564449 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 146
Study 17900321 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), twice daily for 14 days
Number of subjects: 41
Study 17900321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16231754 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in treated hypertensive group (n = 70)
Number of subjects: 558
Study 16231754 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in normotensive group (n = 558)
Number of subjects: 558
Study 16231754 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements in untreated hypertensive group (n = 72)
Number of subjects: 558
Study 16231754 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of morning home blood pressure in patients taking antihypertensive drugs
Number of subjects: 558
Study 12228843 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4500
Study 12228843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4500
Study 12228843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mainly hydrochlorothiazide)
Number of subjects: 4500
Study 10088180 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol p.os 0.5‐1.0 microgram after each dialysis session for 36 months
Number of subjects: 19
Study 10088180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcitriol treatment)
Number of subjects: 19
Study 8527710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg orally per day for 6 months
Number of subjects: 30
Study 8527710 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched sex, age, and initial serum ALT levels)
Number of subjects: 30
Study 8527710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 30
Study 2334614 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose i.v. during surgery
Number of subjects: 30
Study 2334614 — intervention group
Group type: COMPARATOR
Intervention: Ringer‐acetate as the only crystalloid peroperative fluid
Number of subjects: 30
Study 7190412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate and phenformin
Number of subjects: 11
Study 7190412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7190412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 11
Study 7190412 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate and biguanide treatment
Number of subjects: 11
Study 31690536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse reproductive health app
Number of subjects: 1304
Study 31690536 — intervention group
Group type: COMPARATOR
Intervention: General health app
Number of subjects: 1304
Study 30115068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant extract based supplement
Number of subjects: 62
Study 30115068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26831610 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg once daily with lifestyle modification (TL)
Number of subjects: 50
Study 26831610 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (L)
Number of subjects: 50
Study 24284498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 70
Study 24284498 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet (150 mmol)
Number of subjects: 70
Study 24284498 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (400 mmol)
Number of subjects: 70
Study 23362618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MF59-adjuvanted A/H5N1 vaccine (3.75 μg)
Number of subjects: 722
Study 23362618 — intervention group
Group type: COMPARATOR
Intervention: Licensed higher-dose A/H5N1 vaccine (7.5 mg)
Number of subjects: 722
Study 23362618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (low-dose and licensed)
Number of subjects: 722
Study 19573142 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Oral Tolerance Induction (SOTI)
Number of subjects: 200
Study 18581679 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus laser
Number of subjects: 96
Study 18581679 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 96
Study 18581679 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 96
Study 16834647 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic lidocaine injection (5 mL of 2% lidocaine solution injected near the junction of the seminal vesicle with the base of the prostate)
Number of subjects: 90
Study 16834647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel (20 mL of 2% lidocaine gel intrarectally)
Number of subjects: 90
Study 16834647 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (5 mL normal saline injected along the neurovascular bundles)
Number of subjects: 90
Study 14557840 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-made spacer with salbutamol (100 microg/3 kg)
Number of subjects: 54
Study 14557840 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol (250 microg/3 kg)
Number of subjects: 54
Study 10574640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg chlormadinone acetate
Number of subjects: 45
Study 10574640 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel
Number of subjects: 45
Study 8623152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine emulsion capsules
Number of subjects: 101
Study 8623152 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (oral solution for microemulsion)
Number of subjects: 101
Study 1778088 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac dispersible 3-times daily for 4 weeks
Number of subjects: 314
Study 1778088 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3-times daily for 4 weeks
Number of subjects: 314
Study 1778088 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac dispersible
Number of subjects: 314
Study 1778088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 6988335 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary suture and plaster‐of‐Paris
Number of subjects: 95
Study 6988335 — intervention group
Group type: COMPARATOR
Intervention: Plaster‐of‐Paris only
Number of subjects: 95
Study 6988335 — intervention group
Group type: COMPARATOR
Intervention: Strapping
Number of subjects: 95
Study 30590387 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 376
Study 30590387 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (thiazide-like diuretic)
Number of subjects: 376
Study 30590387 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 376
Study 27882611 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate (CL) supplementation
Number of subjects: 18
Study 27882611 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 18
Study 27882611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 25832522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT) for 12 months
Number of subjects: 74
Study 25832522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 74
Study 25832522 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (Control)
Number of subjects: 74
Study 23524942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2 on days 1 and 2) and capecitabine (750 mg/m2 in two divided doses from day 1-14)
Number of subjects: 153
Study 23524942 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2 on days 1 and 2) and 5-FU (750 mg/m2 on days 1, 2, and 3)
Number of subjects: 153
Study 23524942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and capecitabine
Number of subjects: 153
Study 23524942 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and 5-FU
Number of subjects: 153
Study 21596292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopexy
Number of subjects: 42
Study 21596292 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 42
Study 21596292 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 42
Study 19671877 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab with daily blinded budesonide (group A)
Number of subjects: 115
Study 19671877 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab with placebo (group B)
Number of subjects: 115
Study 17334898 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the Rutter parent questionnaire
Number of subjects: 400
Study 17334898 — intervention group
Group type: COMPARATOR
Intervention: Standard version of the Rutter parent questionnaire
Number of subjects: 400
Study 15076126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse internship program
Number of subjects: 0
Study 11322052 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Doubling Perimetry (FDP)
Number of subjects: 45
Study 11322052 — intervention group
Group type: COMPARATOR
Intervention: Standard Automated Perimetry (HFA)
Number of subjects: 45
Study 9466064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin/dexamethasone spray (Otomize)
Number of subjects: 0
Study 9466064 — intervention group
Group type: COMPARATOR
Intervention: Neomycin/dexamethasone drops
Number of subjects: 0
Study 8192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention treatment
Number of subjects: 110
Study 8192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step recovery support group
Number of subjects: 110
Study 8192128 — intervention group
Group type: COMPARATOR
Intervention: Both treatment conditions
Number of subjects: 110
Study 8192128 — intervention group
Group type: COMPARATOR
Intervention: Treatment attendance
Number of subjects: 110
Study 3115445 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with larger cuffs (various lengths and widths)
Number of subjects: 37
Study 3115445 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with six cuffs of various lengths and widths
Number of subjects: 37
Study 3115445 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory blood pressure measurement with a single long bladdered cuff
Number of subjects: 37
Study 30510080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 246
Study 30510080 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 246
Study 27849563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 897
Study 25602857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (ECR) consisting of 8 weeks of aerobic exercise at 70-85% of maximal heart rate during 3 sessions weekly plus usual care
Number of subjects: 96
Study 25602857 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving only usual care
Number of subjects: 96
Study 23777763 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF) combined with recombinant factor VIII (rFVIII)
Number of subjects: 32
Study 23777763 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF)
Number of subjects: 32
Study 23777763 — intervention group
Group type: EXPERIMENTAL
Intervention: post‐rVWF‐rFVIII infusion
Number of subjects: 32
Study 20579832 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confrontation method (SCM), 6 or 12 sessions
Number of subjects: 42
Study 20579832 — intervention group
Group type: COMPARATOR
Intervention: Self-confrontation method (SCM), 6 sessions
Number of subjects: 42
Study 19236972 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral posteroanterior (PA) mobilization technique on the painful side
Number of subjects: 60
Study 19236972 — intervention group
Group type: COMPARATOR
Intervention: Random mobilization technique
Number of subjects: 60
Study 16843248 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine evaluation
Number of subjects: 492
Study 16843248 — intervention group
Group type: COMPARATOR
Intervention: In-person evaluation
Number of subjects: 492
Study 15127875 — intervention group
Group type: EXPERIMENTAL
Intervention: BFEO (brushing, flossing and rinsing with an EO-containing mouthrinse)
Number of subjects: 246
Study 15127875 — intervention group
Group type: EXPERIMENTAL
Intervention: BFC (brushing, flossing and rinsing with a control mouthrinse)
Number of subjects: 246
Study 15127875 — intervention group
Group type: COMPARATOR
Intervention: BC (brushing and rinsing with a control mouthrinse)
Number of subjects: 246
Study 15127875 — intervention group
Group type: EXPERIMENTAL
Intervention: BFEO
Number of subjects: 246
Study 11726440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate extubation (Group 1)
Number of subjects: 50
Study 11726440 — intervention group
Group type: COMPARATOR
Intervention: Delayed extubation (Group 2)
Number of subjects: 50
Study 8996345 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms desmopressin tablets
Number of subjects: 66
Study 8996345 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms desmopressin tablets
Number of subjects: 66
Study 8996345 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms nasal spray
Number of subjects: 66
Study 8996345 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets (both doses)
Number of subjects: 66
Study 8424470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (100 mg median nightly dose for 6 weeks)
Number of subjects: 92
Study 8424470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 weeks)
Number of subjects: 92
Study 8424470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 92
Study 3307548 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanidid (9 mg X kg‐1 IVD, and 60 mg X kg‐1 X h‐1)
Number of subjects: 30
Study 3307548 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg X kg‐1 IVD, and 9 mg X kg‐1 X h‐1)
Number of subjects: 30
Study 29466550 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (Van Riper, 1939)
Number of subjects: 13
Study 29466550 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion points (Smit, 2000)
Number of subjects: 13
Study 26871730 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electrical pharyngeal stimulation (EPS)
Number of subjects: 20
Study 26871730 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical pharyngeal stimulation (EPS)
Number of subjects: 20
Study 24553365 — intervention group
Group type: EXPERIMENTAL
Intervention: imatinib+interferon (IFN)
Number of subjects: 403
Study 24553365 — intervention group
Group type: COMPARATOR
Intervention: imatinib-400mg
Number of subjects: 403
Study 24553365 — intervention group
Group type: COMPARATOR
Intervention: imatinib+cytarabine
Number of subjects: 403
Study 24553365 — intervention group
Group type: COMPARATOR
Intervention: imatinib-600mg
Number of subjects: 403
Study 24553365 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF low levels at diagnosis
Number of subjects: 403
Study 22562977 — intervention group
Group type: COMPARATOR
Intervention: adalimumab therapy
Number of subjects: 76
Study 20581215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 162
Study 20581215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg
Number of subjects: 162
Study 20581215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 20581215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg, Pregabalin 75 mg, Placebo
Number of subjects: 162
Study 17761540 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 298
Study 15935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-free polymer crowns with chamfer finishing line or shoulder preparation
Number of subjects: 114
Study 15935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient evaluation of esthetic and functional performance
Number of subjects: 114